Drugs that contain Hydrocodone Bitartrate

1. List of Hysingla Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8529948 PURDUE PHARMA LP Pharmaceutical formulation containing gelling agent
Aug, 2022

(5 months ago)

US10369109 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(4 months from now)

US9675610 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(4 months from now)

US8309060 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(9 months from now)

US10130591 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(9 months from now)

US11304908 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9095614 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9545380 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492391 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492390 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9763933 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9095615 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9770416 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9486413 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9084816 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9486412 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9775809 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492389 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US11304909 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9750703 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US9872837 PURDUE PHARMA LP Tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US9572779 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US8808740 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US9861584 PURDUE PHARMA LP Tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

Market Authorisation Date: 20 November, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of HYSINGLA ER before it's patent expiration?
More Information on Dosage

2. List of Vantrela Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216176 TEVA BRANDED PHARM Abuse resistant drug formulation
Sep, 2027

(4 years from now)

US9572803 TEVA BRANDED PHARM Abuse resistant drug formulation
Sep, 2027

(4 years from now)

US8445018 TEVA BRANDED PHARM Abuse resistant drug formulation
Jul, 2029

(6 years from now)

Market Authorisation Date: 17 January, 2017

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

3. List of Zohydro Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265760 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(10 years from now)

US9339499 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(10 years from now)

US9433619 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(10 years from now)

US9421200 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(10 years from now)

US9610286 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(10 years from now)

US9333201 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(10 years from now)

US10028946 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(10 years from now)

US10456393 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(10 years from now)

US10722511 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(10 years from now)

US10322120 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(10 years from now)

US9326982 RECRO GAINESVILLE Treating pain in patients with hepatic impairment
Jul, 2033

(10 years from now)

US9486451 RECRO GAINESVILLE Abuse resistant pharmaceutical compositions
Sep, 2034

(11 years from now)

US10092559 RECRO GAINESVILLE Abuse resistant pharmaceutical compositions
Sep, 2034

(11 years from now)

US9452163 RECRO GAINESVILLE Abuse resistant pharmaceutical compositions
Sep, 2034

(11 years from now)

US9132096 RECRO GAINESVILLE Abuse resistant pharmaceutical compositions
Sep, 2034

(11 years from now)

US9713611 RECRO GAINESVILLE Abuse resistant pharmaceutical compositions
Sep, 2034

(11 years from now)

Market Authorisation Date: 25 October, 2013

Treatment: Treatment of pain in patients with hepatic impairment; Treatment of pain

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of ZOHYDRO ER before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic